Contiga Logo.jpg
Cotinga Pharmaceuticals Doses First Patient With Combination Therapy in Phase 1b/2a Trial of COTI-2
15. Januar 2019 08:00 ET | Cotinga Pharmaceuticals Inc.
TORONTO and BOSTON, Jan. 15, 2019 (GLOBE NEWSWIRE) -- Cotinga Pharmaceuticals Inc. (TSX Venture: COT) (“Cotinga” or the “Company”), a clinical-stage pharmaceutical company advancing a pipeline of...
Contiga Logo.jpg
Cotinga Pharmaceuticals Enrolls Two Patients for Combination Therapy in Phase 1b/2a Trial of COTI-2
08. Januar 2019 12:20 ET | Cotinga Pharmaceuticals Inc.
TORONTO and BOSTON, Jan. 08, 2019 (GLOBE NEWSWIRE) -- Cotinga Pharmaceuticals Inc. (TSX Venture: COT) (“Cotinga” or the “Company”), a clinical-stage pharmaceutical company advancing a pipeline of...
Contiga Logo.jpg
Cotinga Pharmaceuticals Reports Fiscal 2019 Second Quarter Financial and Operating Results
03. Januar 2019 12:32 ET | Cotinga Pharmaceuticals Inc.
TORONTO and BOSTON, Jan. 03, 2019 (GLOBE NEWSWIRE) -- Cotinga Pharmaceuticals Inc. (TSX Venture: COT; OTCQB: COTQF) (“Cotinga” or the “Company”), a clinical-stage pharmaceutical company advancing a...
Contiga Logo.jpg
Cotinga Pharmaceuticals Announces Research Partnership with St. Vincent’s University Hospital to Evaluate COTI-2
05. November 2018 08:00 ET | Cotinga Pharmaceuticals Inc.
TORONTO and BOSTON, Nov. 05, 2018 (GLOBE NEWSWIRE) -- Cotinga Pharmaceuticals Inc. (TSX Venture: COT; OTCQB: COTQF) (“Cotinga” or the “Company”), a clinical-stage pharmaceutical company advancing a...
Contiga Logo.jpg
Cotinga Pharmaceuticals Reports Fiscal 2019 First Quarter Financial and Operating Results
02. Oktober 2018 08:00 ET | Cotinga Pharmaceuticals Inc.
TORONTO and BOSTON, Oct. 02, 2018 (GLOBE NEWSWIRE) -- Cotinga Pharmaceuticals Inc. (TSX Venture: COT; OTCQB: COTQF) (“Cotinga” or the “Company”), a clinical-stage pharmaceutical company advancing a...
Contiga Logo.jpg
Cotinga Pharmaceuticals Announces Presentation on COTI-2 at 11th International Symposium on Translational Research in Oncology
19. September 2018 08:00 ET | Cotinga Pharmaceuticals Inc.
TORONTO and BOSTON, Sept. 19, 2018 (GLOBE NEWSWIRE) -- Cotinga Pharmaceuticals Inc. (TSX Venture: COT; OTCQB: COTQF) (“Cotinga” or the “Company”), a clinical-stage pharmaceutical company advancing a...
Contiga Logo.jpg
Cotinga Pharmaceuticals Reports Fiscal 2018 Fourth Quarter and Full Year Financial and Operating Results
29. August 2018 08:00 ET | Cotinga Pharmaceuticals Inc.
TORONTO and BOSTON, Aug. 29, 2018 (GLOBE NEWSWIRE) -- Cotinga Pharmaceuticals Inc. (TSX Venture: COT; OTCQB: COTQF) (“Cotinga” or the “Company”), a clinical-stage pharmaceutical company advancing a...
Contiga Logo.jpg
Cotinga Pharmaceuticals Announces Management and Board Changes
02. Juli 2018 16:30 ET | Cotinga Pharmaceuticals Inc.
LONDON, Ontario and BOSTON, July 02, 2018 (GLOBE NEWSWIRE) -- Cotinga Pharmaceuticals Inc. (TSX Venture:COT) (OTCQB:COTQF) (“Cotinga” or the “Company”), a clinical-stage pharmaceutical company...
Contiga Logo.jpg
Cotinga Pharmaceuticals Announces FDA Clearance of Significant Protocol Changes for COTI-2 Clinical Program
24. Mai 2018 08:00 ET | Cotinga Pharmaceuticals Inc.
LONDON, Ontario and BOSTON, May 24, 2018 (GLOBE NEWSWIRE) -- Cotinga Pharmaceuticals Inc. (TSX-V:COT) (OTCQB:COTQF) (“Cotinga” or the “Company”), a clinical-stage pharmaceutical company advancing a...
Contiga Logo.jpg
Cotinga Pharmaceuticals Announces Presentation on COTI-2 at the 2018 American Society of Clinical Oncology Annual Meeting
17. Mai 2018 07:30 ET | Cotinga Pharmaceuticals Inc.
LONDON, Ontario and BOSTON, May 17, 2018 (GLOBE NEWSWIRE) -- Cotinga Pharmaceuticals Inc. (TSX Venture:COT) (OTCQB:COTQF) (“Cotinga” or the “Company”), a clinical-stage pharmaceutical company...